BioAge Labs’ Post

An interesting read from Tony Kulesa discussing the future of #biotech, emphasizing the importance of founder-led #ventures. Tony discusses: - How a #founder's vision and passion drives innovation - The intersection/collaboration between #scientists and #entrepreneurs - Rapid advancements in #precisionmedicine - Ethical considerations in biotech breakthroughs Examples of founder-led biotechs already leading the way include: - LatchBio (Alfredo Andere 🦖, Kyle Giffin, Kenny Workman) - 64x Bio (Lexi Rovner, Jeffrey Way) - Mammoth Biosciences (Janice Chen, Lucas Harrington) - Mytos (Ignacio Willats, Ali Afshar) - Phytoform (Nicolas Kral, PhD, William Pelton)

Are you ready for positive change? 💡 The US biotech industry is seeing a transformative wave of investments that's not just about business — it's about changing lives for the better. Investment trends ➡️ Signal a promising future for both innovators and patients alike. It's about going beyond the bottom line to impact health on a global scale. We're witnessing a surge in funding that empowers biotech firms to breakthrough with next-gen treatments. Why does this matter? Because it's investment with purpose. It's capital that's building a healthier tomorrow. Consider this: recent backing of cutting-edge gene therapies, or the dollars funneling into personalized medicine. These aren't just investment stories; these are chapters in a bigger narrative of hope and healing. Here's where the real magic happens. With a solid funding foundation, small biotechs are scaling up quickly, bringing daring solutions from the lab to the lives that need them most. It's a powerful narrative — one where backing bold ideas leads to life-saving results. And that's what we're all about at i-Pharm. We're not just filling positions. We're helping to accelerate this movement, connecting the brightest minds in life sciences with opportunities to make a real-world impact. Want to be part of this life science revolution? Let's talk and make connections that count. #BiotechInvestment #LifeSciences #HealthcareInnovation

In today's rapidly evolving landscape, Biotechs stand out as a beacon of innovation and potential for investors. The realm of biotechnology offers a unique blend of groundbreaking scientific advancements and promising investment opportunities. As we navigate the current investment environment, Biotechs continue to attract attention due to their potential to revolutionize healthcare, agriculture, and beyond. The fusion of biology and technology not only drives scientific progress but also presents lucrative prospects for those keen on investing in the future. With ongoing developments in gene editing, personalized medicine, and biopharmaceuticals, the Biotech sector remains dynamic and full of promise. Investors looking to diversify their portfolios and tap into transformative technologies are increasingly turning their focus towards Biotechs. Amidst this backdrop, staying informed about the latest trends, breakthroughs, and regulatory updates is key to making informed investment decisions in the Biotech space. Whether you're a seasoned investor or someone exploring new avenues, keeping a pulse on Biotechs can unveil exciting opportunities for growth and impact. Let's embrace the potential of Biotechs together and pave the way for a future where science, innovation, and investments converge to shape a better tomorrow. #Biotech #Investments #Innovation #FutureProofInvesting

🚀 Exciting News in Biotech! 🧬 Arena BioWorks emerges as a cutting-edge biomedical research powerhouse, committed to turning breakthroughs into lifesaving treatments! Co-founded by luminary figures like Harvard's Stuart Schreiber, Steve Pagliuca of Bain Capital fame, and VC innovator Tom Cahill, this institute is on a mission to revolutionize drug development. Leveraging private investments, Arena BioWorks aims to fast-track discoveries from the lab to the market. Get ready for a new wave of for-profit biotech ventures that could change the face of healthcare as we know it! Dive into the details and see what's on the biomedical horizon! #Biotech #Innovation #Healthcare #ArenaBioWorks 💡💊

10 best U.S. cities for biopharma (according to annual ranking by GEN) 🏆 Genetic Engineering & Biotechnology News, or GEN for short, has published annual rankings since 2014, and there were 5 criteria for the list this year: ✔ 𝐍𝐈𝐇 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 ✔ 𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐜𝐚𝐩𝐢𝐭𝐚𝐥 (𝐕𝐂) 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 ✔ 𝐏𝐚𝐭𝐞𝐧𝐭𝐬 ✔ 𝐋𝐚𝐛 𝐬𝐩𝐚𝐜𝐞 ✔ 𝐉𝐨𝐛𝐬 Now for the list itself! Based on the criteria above, the rankings for 2023 are: (drumroll please 🥁) 𝟏𝟎. 𝐂𝐡𝐢𝐜𝐚𝐠𝐨𝐥𝐚𝐧𝐝 𝟗. 𝐒𝐞𝐚𝐭𝐭𝐥𝐞 𝟖. 𝐍𝐨𝐫𝐭𝐡 𝐂𝐚𝐫𝐨𝐥𝐢𝐧𝐚 𝟕. 𝐆𝐫𝐞𝐚𝐭𝐞𝐫 𝐏𝐡𝐢𝐥𝐚𝐝𝐞𝐥𝐩𝐡𝐢𝐚 𝟔. 𝐒𝐚𝐧 𝐃𝐢𝐞𝐠𝐨 𝟓. 𝐋𝐨𝐬 𝐀𝐧𝐠𝐞𝐥𝐞𝐬 / 𝐎𝐫𝐚𝐧𝐠𝐞 𝐂𝐨𝐮𝐧𝐭𝐲 𝟒. 𝐍𝐞𝐰 𝐘𝐨𝐫𝐤 / 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲 𝟑. 𝐁𝐢𝐨𝐇𝐞𝐚𝐥𝐭𝐡 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐑𝐞𝐠𝐢𝐨𝐧 [𝐌𝐚𝐫𝐲𝐥𝐚𝐧𝐝/𝐕𝐢𝐫𝐠𝐢𝐧𝐢𝐚/𝐖𝐚𝐬𝐡𝐢𝐧𝐠𝐭𝐨𝐧, 𝐃.𝐂.] 𝟐. 𝐁𝐨𝐬𝐭𝐨𝐧/𝐂𝐚𝐦𝐛𝐫𝐢𝐝𝐠𝐞 𝟏. 𝐒𝐚𝐧 𝐅𝐫𝐚𝐧𝐜𝐢𝐬𝐜𝐨 𝐁𝐚𝐲 𝐀𝐫𝐞𝐚 Having lived and worked in Massachusetts myself since 2020, it's reassuring to see Boston/Cambridge so high up on the list, but also slightly disappointing to see it slip from the number 1 spot, which the cluster has occupied on GEN's list since 2015. The reason for this? While the region leads in terms of lab space, there has been a bit of a dip in both patents and venture capital. This is likely a result of last year's bear market, but a market recovery this year could bring Boston/Cambridge back to the top of the list, de-throning the Bay Area. A little friendly competition between the two doesn't hurt 😉 What are your thoughts on this year's ranking? Source: https://lnkd.in/eh7khq-R #biotechnology #pharma #funding #venturecapital #labspace --- Hi, I'm Jeff Bissen (pronounced BEE-sen) 👋 I help research teams with fully open automation for IHC (immunohistochemistry) and FISH (fluorescence in situ hybridization). I also post biotech content almost every weekday. Interested? ➕ Follow my profile 🔔 Click the bell 🤝 Connect with me ✉ Send a message 👍 Like the post 👇 Leave a comment

A 2018 article from Nature found that more than 50% of biological research may not be reproducible. This problem is especially evident in longevity science, and is one of the largest hurdles to innovation. Before investing in a new company, Ichor makes a point to directly validate findings by replicating results. Longevity Technology released an interview with CEO Kelsey Moody today about why this is important, you can check it out here: https://lnkd.in/eyJQHWiH #biotech #innovation #ichorlifesciences #drugdevelopment

🔬🎉 The impact of European biotech on global health and wellness is both far-reaching and groundbreaking. 🌎 From developments in gene-editing to advances in cancer treatments, Europe has become a hub of medical innovation. 💊 This has allowed for greater access to healthcare resources, resulting in healthier and happier lives for many people around the world. 🤗 Not only that, but the increased focus on research and development has also allowed for the discovery of new treatments, drugs, and vaccines that can help in the fight against some of the world's most pressing diseases. 💉 European biotech is truly making a difference in the global health landscape, and we are incredibly proud to be a part of it. 🤝 #Biotech #EuropeanInnovation #GlobalHealthAndWellness

💲 1 BILLION DOLLAR INVESTMENT 💲 Last week, Xaira Therapeutics announced their initial funding release of over $1 billion. Xaira is set to combine AI research, extensive data generation, and therapeutic product development to accelerate the delivery of effective therapies to patients. Co-founded by renowned scientists and backed by leading investors, Xaira's platform integrates cutting-edge machine learning research with comprehensive biological data sets to inform the development of novel therapeutics. Led by experienced executives, including Dr. Marc Tessier-Lavigne, the company is poised to reshape the landscape of drug discovery with its multidisciplinary approach and transformative vision. Xaira brings together three core elements: 1. Advanced machine learning research 2. Expansive data generation to power new model 3. Robust therapeutic product development. “Driven by growing data sets and new methods, there has been accelerating progress in artificial intelligence and its applications to medicine, biology and chemistry, including seminal work from David Baker’s lab at the Institute for Protein Design,” said Dr. Vikram Bajaj, CEO of Foresite Labs and Managing Director of Foresite Capital. #xairatherapeutics #xaira #funding #biotech #innovation

Unlocking innovation – how to take your research idea from concept to reality! We invited researchers and entrepreneurs in Norway to our drug discovery seminar co-hosted with ShareLab at Forskningsparken - Oslo Science Park.  We were thrilled to have Georg Vo Beiske at Tribune Therapeutics share his experience with us.    During the seminar, we also tackled several interesting questions from the audience. One of those were - toxicity studies versus compound optimization, at which end do you start? Focus on the big picture and use a balanced approach. The winner is likely not the one with the absolute best solubility or potency. A compound with a good overall profile can go far too! Our seminar also emphasized the importance of designing your "killer" experiment early in the process. How will your compound compare to the treatments available on the market? By anticipating the toughest questions from potential investors and stakeholders, you can ensure your drug stands out from the rest!

 🔆 Exciting News for Investors in Biotech Innovation! 🔆 We are thrilled to share a major milestone for FUTR BIO, where innovation meets impact in biotech. Our recent proof-of-concept preclinical data demonstrates compelling results: our mRNA vaccine platform delivers robust protection at low doses, promising long-term safety and efficacy. This breakthrough underscores our commitment to revolutionizing healthcare through synthetic biology. Learn more about our groundbreaking approach: https://futr.bio/ Why Invest in FUTR BIO?  ✨Advanced Technology: Harnessing synthetic biology to pioneer next-gen therapies.  ✨Market Potential: Addressing critical medical needs with scalable solutions.  ✨Proven Results: Exciting preclinical data supports vaccine effectiveness and safety. ✨ Experienced Team: Led by a passionate team of industry experts and visionaries. We invite visionary investors to join us in shaping the future of biotechnology. Let’s collaborate to bring these transformative solutions to the global stage. Curious to learn more about our journey? Let's connect and explore how you can contribute to the FUTR BIO vision! #BiotechInnovation #HealthcareRevolution #InvestInFutrBio #SyntheticBiology #StartupInvestment #HealthTech